37631 |
Oncology; Respiratory System |
Real world data of durvalumab consolidation after chemoradiotherapy in... |
LUNG CANCER 2020 10.1016/j.lungcan.2020.05.035 |
박근칠 |
2020 |
37630 |
Oncology |
Biomarker-driven phase 2 umbrella trial study for patients with recurr... |
CANCER 2020 10.1002/cncr.33048 |
박근칠 |
2020 |
37629 |
Cardiac & Cardiovascular Systems; Respiratory System; Surgery |
Utility of positron emission-computed tomography for predicting pathol... |
EUR J CARDIO-THORAC 2020 10.1093/ejcts/ezaa181 |
박근칠 |
2020 |
37628 |
Oncology; Respiratory System |
The different central nervous system efficacy among gefitinib, erlotin... |
TRANSL LUNG CANCER R 2020 10.21037/tlcr-20-379 |
박근칠 |
2020 |
37627 |
Critical Care Medicine; Respiratory System |
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell l... |
LANCET RESPIR MED 2020 10.1016/S2213-2600(20)30154-5 |
박근칠 |
2020 |
37626 |
Multidisciplinary Sciences |
Regulatory -(FoxP3(+)) T cells and TGF-beta predict the response to an... |
SCI REP-UK 2020 10.1038/s41598-020-76130-1 |
박근칠 |
2020 |
37625 |
Oncology |
Ramucirumab or placebo plus erlotinib inEGFR-mutated, metastatic non-s... |
CANCER SCI 2020 10.1111/cas.14655 |
박근칠 |
2020 |
37624 |
Oncology |
Ramucirumab and durvalumab for previously treated, advanced non-small-... |
EUR J CANCER 2020 10.1016/j.ejca.2020.06.007 |
박근칠 |
2020 |
37623 |
Oncology |
Phase III study of selpercatinib vs chemotherapy plus /- pembrolizumab... |
FUTURE ONCOL 2020 10.2217/fon-2020-0935 |
박근칠 |
2020 |
37622 |
Oncology; Respiratory System |
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NS... |
J THORAC ONCOL 2020 10.1016/j.jtho.2020.06.018 |
박근칠 |
2020 |